text Therapeutics (US:CNTX) Globenewswireยท2025-08-06 20:11Core Insights - Context Therapeutics Inc. is advancing its clinical pipeline with two bispecific antibodies, CTIM-76 and CT-95, and expects to share initial dose escalation data in 2026 [2][3] - The company reported cash and cash equivalents of $83.5 million as of June 30, 2025, which is projected to fund operations into 2027 [1][10] - The net loss for the second quarter of 2025 was $8.8 million, compared to a loss of $2.3 million in the same period of 2024 [6][9] Pipeline Updates - CTIM-76 is a selective Claudin 6 x CD3 bispecific antibody, while CT-95 is an avidity enhanced mesothelin x CD3 bispecific antibody [2][7] - The company plans to initiate a first-in-human trial for CT-202, a Nectin-4 x CD3 bispecific antibody, in the second quarter of 2026 [2] Financial Performance - Research and development expenses for Q2 2025 were $7.8 million, significantly higher than $1.4 million in Q2 2024, driven by increased costs associated with CT-202, CT-95, and CTIM-76 [5][9] - General and administrative expenses rose to $1.9 million in Q2 2025 from $1.7 million in Q2 2024, primarily due to higher personnel-related costs [5][9] - Other income for Q2 2025 was approximately $0.9 million, slightly up from $0.8 million in Q2 2024, mainly due to increased interest income [5][9] Corporate Updates - The company appointed Dr. Karen Chagin as Chief Medical Officer in June 2025 [5] - Context Therapeutics presented at several conferences, including the ASCO Annual Meeting and the AACR Annual Meeting in 2025 [5]